skip to Main Content

2022-2026 Global Gene Editing Market Analysis, With

Dublin, April 19, 2022 (GLOBE NEWSWIRE) — The “Global Gene Editing Market Report 2022, By Technology, By End Users, By Application” report has been added to from offer.

The global gene editing market is expected to grow from $5.41 billion in 2021 to $6.35 billion in 2022 at a compound annual growth rate (CAGR) of 17.2%. The market is expected to reach $12.04 billion in 2026 with a CAGR of 17.4%.

One of the major drivers of the gene editing market is the rise in infectious diseases. Gene editing techniques are used for the detection of infectious diseases such as HIV. Infectious diseases are caused by microorganisms such as bacteria, viruses, fungi and parasites. Gene therapy treats infectious diseases by blocking the replication of the infectious agent that causes the disease at the extracellular level. Gene editing introduces new genetic material into the cells of living organisms for the purpose of treating disease.

Infectious diseases are constantly on the rise. For example, according to the World Health Organization (WHO), infectious diseases kill more than 17 million people a year. On top of that, according to the AP-NORC survey (a research initiative of the Associated Press and the University of Chicago), out of 1,067 adults surveyed in the United States, 71% favor editing genes for the treatment of incurable diseases, inherited diseases such as Huntington’s disease and 67% of Americans support the use of gene editing to prevent diseases such as cancer.

One of the major market restraining factors is the ethical concerns of the general public regarding gene editing. Many researchers and ethicists have opposed gene editing for different reasons such as off-target effect (edits in the wrong place), mosaicism and safety concerns. Some have even argued that gene editing will lead to the creation of classes of individuals who will be genetically engineered to be able to do things that a normal human being is not supposed to do according to the laws of nature. For these reasons, gene editing is still not considered safe and effective by many countries and international organizations.

The European regulatory framework has divided gene therapy into two categories, germline gene therapy and somatic gene therapy. In germline gene therapy, the modified genes will be passed on to subsequent generations whereas this is not the case with somatic gene therapy. Current EU regulations only allow somatic gene therapy, therefore germline gene therapy is prohibited. The European Medical Association provides gene therapy guidelines for the preparation of a marketing authorization application to obtain approval from the authority to carry out research and development activities in therapy gene. For example, the EU provides a guidance note on gene therapy medicinal products for use in humans, defines scientific principles and provides guidance for the development and evaluation of gene therapy products.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market.

  • It traces historical and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size (in billions of dollars) covering both the historical market growth, the impact of the COVID-19 virus and the forecast of its recovery.
  • Market segmentations break down the market into sub-markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the market size by geography and compares their historical and forecast growth.
  • It covers the impact and recovery trajectory of COVID-19 for all regions, major developed countries and major emerging markets.
  • The competitive landscape gives a description of the competitive nature of the market, market shares and a description of the major companies.
  • The main financial transactions that have shaped the market in recent years are identified.
  • The trends and strategies section analyzes the shape of the market coming out of the crisis and suggests how companies can grow as the market recovers.


Covered markets:

  • By technology: CRISPR; TALEN; ZFN
  • By end users: biotechnology; Pharmaceutical; Contract Research Organization
  • By Application: Animal Genetic Engineering; plant genetic engineering; Cell line engineering

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; UNITED STATES

Regions: Asia Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Companies cited

  • GenScript USA Inc.
  • Horizon Discovery Group plc
  • Integrated DNA Technologies
  • New England Biolabs
  • OriGene Technologies
  • Thermo Fisher Scientific
  • Merck KgaA
  • GenScript Company
  • Editas Medicine
  • Lonza Group
  • Sangamo
  • DNA 2.0
  • BioRAD
  • allele
  • Addgene
  • Sigma-Aldrich Corporation
  • Transposagen Biopharmaceuticals
  • Recombinant
  • Precision Biosciences
  • Promega
  • Juno Therapeutic
  • Therapeutic Intellia
  • Qiagen
  • GE Healthcare Lonza
  • Cellectis
  • dharmacon
  • Astra Zeneca
  • AgilentTechnologies

For more information on this report, visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Back To Top